Whole-genome sequencing in personalized therapeutics

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 6, 2012, Pages 1001-1009

  Cordero, P ^a   Ashley, E A ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPY; CLINICAL ASSESSMENT; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; PERSONALIZED MEDICINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS; DNA; DRUG THERAPY; GENETIC TESTING; GENETIC VARIATION; GENOME, HUMAN; GENOMIC STRUCTURAL VARIATION; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVENTIVE MEDICINE; PSEUDOGENES; REPETITIVE SEQUENCES, NUCLEIC ACID;

EID: 84861341396     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.51     Document Type: Review

References (81)

1. Venter, J.C. et al. The sequence of the human genome. Science 291, 1304-1351 (2001).
2. Lander, E.S. et al.; International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001). (Pubitemid 32165345)
3. Lenzer, J. & Brownlee, S. Knowing me, knowing you. BMJ 336, 858-860 (2008). (Pubitemid 351580005)
4. Chee-Seng, K., En Yun, L., Yudi, P. & Kee-Seng, C. Genome-wide association studies: the success, failure and future. Wiley Online Library (2001). doi:10.1002/9780470015902.a0021995
5. Witte, J.S. Genome-wide association studies and beyond. Annu. Rev. Public Health 31, 9-20 4 p following 20 (2010).
6. Cooper, G.M. et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022-1027 (2008).
7. Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105-1109 (2009).
8. Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41, 1100-1104 (2009).
9. Shuldiner, A.R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849-857 (2009).
10. Link, E. et al.; SEARCH Collaborative Group. SLCO1B1 variants and statininduced myopathy-a genomewide study. N. Engl. J. Med. 359, 789-799 (2008).
11. Daly, A.K. et al.; DILIGEN Study; International SAE Consortium. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41, 816-819 (2009).
12. Johnson, D.C. et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J. Clin. Oncol. 29, 797-804 (2011).
13. Daly, A.K. Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Med. 1, 10 (2009).
14. Manolio, T.A. et al. Finding the missing heritability of complex diseases. Nature 461, 747-753 (2009).
15. Ng, S.B. et al. Exome sequencing identifies the cause of a Mendelian disorder. Nat. Genet. 42, 30-35 (2010).
16. Ng, S.B. et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat. Genet. 42, 790-793 (2010).
17. Hoischen, A. et al. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. Nat. Genet. 42, 483-485 (2010).
18. Johnson, J.O. et al.; ITALSGEN Consortium. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68, 857-864 (2010).
19. Bilgüvar, K. et al. Whole-exome sequencing identifies recessive WDR62 mutations in severe brain malformations. Nature 467, 207-210 (2010).
20. Roach, J.C. et al. Analysis of genetic inheritance in a family quartet by wholegenome sequencing. Science 328, 636-639 (2010).
21. Lupski, J.R. et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N. Engl. J. Med. 362, 1181-1191 (2010).
22. Bainbridge, M.N. et al. Whole-genome sequencing for optimized patient management. Sci. Transl. Med. 3, 87re3 (2011).
23. Ashley, E.A. et al. Clinical assessment incorporating a personal genome. Lancet 375, 1525-1535 (2010).
24. Dewey, F.E. et al. Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. PLoS Genet. 7, e1002280 (2011).
25. Iafrate, A.J. et al. Detection of large-scale variation in the human genome. Nat. Genet. 36, 949-951 (2004). (Pubitemid 39167488)
26. Tanaka, T. The International HapMap Project. Nature 426, 789-796 (2003).
27. Cann, H.M. et al. A human genome diversity cell line panel. Science 296, 261-262 (2002). (Pubitemid 34303653)
28. Frazer, K.A., Murray, S.S., Schork, N.J. & Topol, E.J. Human genetic variation and its contribution to complex traits. Nat. Rev. Genet. 10, 241-251 (2009).
29. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007).
30. Sladek, R. et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445, 881-885 (2007).
31. Duerr, R.H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-1463 (2006). (Pubitemid 44871953)
32. Easton, D.F. et al.; SEARCH collaborators; kConFab; AOCS Management Group. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087-1093 (2007). (Pubitemid 47014426)
33. Hinks, A. et al. Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis. Ann. Rheum. Dis. 70, 1395-1400 (2011).
34. Mailman, M.D. et al. The NCBI dbGaP database of genotypes and phenotypes. Nat. Genet. 39, 1181-1186 (2007). (Pubitemid 47482671)
35. Cooper, D.N. & Krawczak, M. Human Gene Mutation Database. Hum. Genet. 98, 629 (1996). (Pubitemid 126745950)
36. Hamosh, A., Scott, A.F., Amberger, J., Valle, D. & McKusick, V.A. Online Mendelian Inheritance in Man. Hum. Mutat. 15, 811-812 (2000).
37. Mullaney, J.M., Mills, R.E., Pittard, W.S. & Devine, S.E. Small insertions and deletions (INDELs) in human genomes. Hum. Mol. Genet. 19, R131-R136 (2010).
38. Zia, A. & Moses, A.M. Ranking insertion, deletion and nonsense mutations based on their effect on genetic information. BMC Bioinformatics 12, 299 (2011).
39. Willcocks, L.C. et al. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J. Exp. Med. 205, 1573-1582 (2008). (Pubitemid 351962021)
40. Marshall, C.R. et al. Structural variation of chromosomes in autism spectrum disorder. Am. J. Hum. Genet. 82, 477-488 (2008).
41. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455, 237-241 (2008).
42. Cappuzzo, F. et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97, 643-655 (2005). (Pubitemid 40812628)
43. Antonarakis, S.E. et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 86, 2206-2212 (1995).
44. Bondeson, M.-L. et al. Inversion of the IDS gene resulting from recombination with IDS-related sequences in a common cause of the Hunter syndrome. Hum. Mol. Genet. 4, 615-621 (1995).
45. Hebbring, S.J., Moyer, A.M. & Weinshilboum, R.M. Sulfotransferase gene copy number variation: pharmacogenetics and function. Cytogenet. Genome Res. 123, 205-210 (2008).
46. Pai, H.V., Kommaddi, R.P., Chinta, S.J., Mori, T., Boyd, M.R. & Ravindranath, V. A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine. J. Biol. Chem. 279, 27383-27389 (2004). (Pubitemid 38812577)
47. Dickson, S.P., Wang, K., Krantz, I., Hakonarson, H. & Goldstein, D.B. Rare variants create synthetic genome-wide associations. PLoS Biol. 8, e1000294 (2010).
48. Holm, H. et al. A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat. Genet. 43, 316-320 (2011).
49. Ramsey, L.B. et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 22, 1-8 (2012).
50. van de Steeg, E. et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J. Clin. Invest. 122, 519-528 (2012).
51. McCarthy, M.I. et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet. 9, 356-369 (2008). (Pubitemid 351556063)
52. Carlini, D.B. & Genut, J.E. Synonymous SNPs provide evidence for selective constraint on human exonic splicing enhancers. J. Mol. Evol. 62, 89-98 (2006). (Pubitemid 43185421)
53. Chen, R., Davydov, E.V., Sirota, M. & Butte, A.J. Non-synonymous and synonymous coding SNPs show similar likelihood and effect size of human disease association. PLoS ONE 5, e13574 (2010).
54. Pasmant, E., Sabbagh, A., Vidaud, M. & Bièche, I. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 25, 444-448 (2011).
55. Ørom, U.A. & Shiekhattar, R. Long non-coding RNAs and enhancers. Curr. Opin. Genet. Dev. 21, 194-198 (2011).
56. McDonagh, E.M., Whirl-Carrillo, M., Garten, Y., Altman, R.B. & Klein, T.E. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark. Med. 5, 795-806 (2011).
57. Morgan, A.A., Chen, R. & Butte, A.J. Likelihood ratios for genome medicine. Genome Med. 2, 30 (2010).
58. Patel, C.J., Bhattacharya, J. & Butte, A.J. An Environment-Wide Association Study (EWAS) on type 2 diabetes mellitus. PLoS ONE 5, e10746 (2010).
59. Roychowdhury, S. et al. Personalized oncology through integrative highthroughput sequencing: a pilot study. Sci. Transl. Med. 3, 111ra121 (2011).
60. Welch, J.S. et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 305, 1577-1584 (2011).
61. Bloss, C.S., Schork, N.J. & Topol, E.J. Effect of direct-to-consumer genomewide profiling to assess disease risk. N. Engl. J. Med. 364, 524-534 (2011).
62. Grant, R.W. et al. Design of a randomized trial of diabetes genetic risk testing to motivate behavior change: the Genetic Counseling/lifestyle Change (GC/LC) Study for Diabetes Prevention. Clin. Trials 8, 609-615 (2011).
63. Chen, R. et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148, 1293-1307 (2012).
64. Tsai, H.C. & Baylin, S.B. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res. 21, 502-517 (2011).
65. Johnstone, S.E. & Baylin, S.B. Stress and the epigenetic landscape: a link to the pathobiology of human diseases? Nat. Rev. Genet. 11, 806-812 (2010).
66. National Center for Health Statistics. Electronic health record systems and intent to apply for meaningful use incentives among office-based physician practices: United States 2001-2011. http://www.cdc.gov/nchs/data/databriefs/ db79.htm (2011).
67. Frueh, F.W. et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 28, 992-998 (2008).
68. Day, I.N. dbSNP in the detail and copy number complexities. Hum. Mutat. 31, 2-4 (2010).
69. Church, D.M. et al. Public data archives for genomic structural variation. Nat. Genet. 42, 813-814 (2010).
70. Zhang, J., Feuk, L., Duggan, G.E., Khaja, R. & Scherer, S.W. Development of bioinformatics resources for display and analysis of copy number and other structural variants in the human genome. Cytogenet. Genome Res. 115, 205-214 (2006). (Pubitemid 44832022)
71. Birney, E. et al.; ENCODE Project Consortium; NISC Comparative Sequencing Program; Baylor College of Medicine Human Genome Sequencing Center; Washington University Genome Sequencing Center; Broad Institute; Children's Hospital Oakland Research Institute. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447, 799-816 (2007). (Pubitemid 46920138)
72. Ng, P.C. & Henikoff, S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812-3814 (2003). (Pubitemid 37442253)
73. Adzhubei, I.A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010).
74. Leinonen, R. et al. The European Nucleotide Archive. Nucleic Acids Res. 39, D28-D31 (2011).
75. Stenson, P.D. et al. The Human Gene Mutation Database: 2008 update. Genome Med. 1, 13 (2009).
76. Mottaz, A., David, F.P., Veuthey, A.L. & Yip, Y.L. Easy retrieval of single amino-acid polymorphisms and phenotype information using SwissVar. Bioinformatics 26, 851-852 (2010).
77. Becker, K.G., Barnes, K.C., Bright, T.J. & Wang, S.A. The genetic association database. Nat. Genet. 36, 431-432 (2004).
78. Hindorff, L.A. et al. Potential etiologic and functional implications of genomewide association loci for human diseases and traits. Proc. Natl. Acad. Sci. USA 106, 9362-9367 (2009).
79. Drmanac, R. et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327, 78-81 (2010).
80. Durbin, R.M. et al. A map of human genome variation from population-scale sequencing. Nature 467, 1061-1073 (2010).
81. Knox, C. et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 39, D1035-D1041 (2011).